Abstract:Amyloid precursor protein (APP) is predominantly located in synapses of neurons and its mutations have been well recognized as the most important genetic causal factor for the familial Alzheimer's disease (AD). While most disease-causal mutations of APP occur within the Aβ-coding region or immediately proximal, the pathological impacts of mutations in the N-terminus of APP protein, which remote from the Aβ sequence, on neuron and synapse are still largely unknown. It was recently reported a pathogenic APP N-terminal Val225Ala mutation (APP V225A ) with clinically featuring progressive dementia and typical AD pathologies in brain. In our present study, we further found that APP V225A mutation alters the N-terminal structure of APP, which enhances its binding affinity to tau protein and significantly increases APP-mediated endocytosis. Consequently, APP V225A promotes the uptake of extracellular tau into SH-SY5Y cells, further linking the structural change in APP to intracellular tau accumulation. In addition, APP V225A also notably alters the liquid-liquid phase separation (LLPS) of intracellular tau and intensified tau phosphorylation and aggregation in SH-SY5Y cells. Moreover, APP V225A promote AD-like tau pathology and synaptic damages in human induced pluripotent stem cells (hiPSCs)-derived neural progenitor cells and neurons, as well as in hiPSCs-derived human brain organoids and mouse brain, which can be ameliorated by tau knockdown. Proximity labeling identified several key APP V225A -interacting proteins, including HS3ST3A1, which was shown to directly regulate tau LLPS and phosphorylation. These findings nicely build on our previous work on roles for APP in tau-related pathological phenotypes and further highlight the involvement of N-terminal APP as the key region for both amyloidopathy and tauopathy, two aspects of AD pathogenesis and progression. Our study may also provide a theoretical breakthrough for AD therapy and highlight the important hub roles of APP and making previously neglected N-terminal APP as a potential target for the discovery of novel disease-modifying therapeutic agents against AD, holding significant scientific values and clinical promise.

Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease

An APP Mutation Family Exhibiting White Matter Hyperintensities and Cortical Calcification in East China

Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease

Probable Novel APP Met671Leu Mutation in a Chinese Han Family with Early-Onset Alzheimer's Disease

Early-Onset Cerebral Amyloid Angiopathy and Alzheimer Disease Related to an APP Locus Triplication

Targeted sequencing on neurodegenerative genes identified novel causal and risk variants of familial Alzheimer's disease

APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases

Polymorphisms in the promoter of the human APP gene: functional evaluation and allele frequencies in Alzheimer disease

Mutation Analysis of Presenilin-1 Gene in Alzheimer' S Disease Patients and the Effects of Its Mutation on Expression of Presenilin-1 and Amyloid Precursor Protein

Novel mutations and repeated findings of mutations in familial Alzheimer disease

Novel APP K724M Mutation Causes Chinese Early-Onset Familial Alzheimer's Disease and Increases Amyloid-Β42 to Amyloid-Β40 Ratio.

Candidate Gene for the Chromosome 1 Familial Alzheimer's Disease Locus

The identification of PSEN1 p.Tyr159Ser mutation in a non-canonic early-onset Alzheimer's disease family

A Rare Variation in the 3' Untranslated Region of the Presenilin 2 Gene is Linked to Alzheimer's Disease.

The Protective A673T Mutation of Amyloid Precursor Protein (APP) in Alzheimer’s Disease

The pathogenic APP N-terminal Val225Ala mutation alters tau protein liquid-liquid phase separation and exacerbates synaptic damage

Identification of a Novel PSEN1 Gly111Val Missense Mutation in a Chinese Pedigree with Early-Onset Alzheimer's Disease

Systematic validation of variants of unknown significance in APP, PSEN1 and PSEN2

Missense and Loss of Function Variants at GWAS Loci in Familial Alzheimer's Disease

P3‐120: MOLECULAR GENETIC ANALYSIS OF APP, PSEN1, AND PSEN2 GENES IN CHINESE PATIENTS WITH ALZHEIMER'S DISEASE

APP Substitutions V715F and L720P Alter PS1 Conformation and Differentially Affect Abeta and AICD Generation.